Trials / Completed
CompletedNCT06422247
Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 307 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the therapeutic practices and the prognosis of patients with relapsed or refractory peripheral T-cell lymphoma in Japan
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Systemic therapy | Approved peripheral T-cell lymphoma systemic treatments prescribed by the treating physician |
Timeline
- Start date
- 2024-04-05
- Primary completion
- 2025-02-05
- Completion
- 2025-02-05
- First posted
- 2024-05-20
- Last updated
- 2025-06-04
Locations
1 site across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06422247. Inclusion in this directory is not an endorsement.